Results We included 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m 2 [IQR 31.438.3]), with 13 patients being treated with GLP-1-RAs
Interrogation of real-world data sets using the Explorys system to assess cancer rates in 300 different healthcare systems in the USA following initiation of GLP-1RA therapy in 64,230 individuals with type 2 diabetes revealed lower rates of prostate, lung and colon cancer, but higher rates of thyroid cancer [164]
Approved in 1964 for the management of hypertension, propranolol is now used for a wide range of cardiovascular diseases, including ischemic heart disease, angina pectoris, arrhythmias, and myocardial infarction, as well as non cardiovascular conditions, including migraine, tremors and anxiety
This partly explains why the weight loss numbers are higher than either semaglutide or tirzepatide
Head-to-head evidence suggests tirzepatide may produce greater average weight loss in eligible trial populations